Carolina Medeiros da Frota Ribeiro1, Patricio Riva-Posse2. 1. Department of Psychiatry and Behavioral Sciences, Emory University, 12 Executive Park Dr., suite 500, Atlanta, GA, 30329, USA. 2. Department of Psychiatry and Behavioral Sciences, Emory University, 12 Executive Park Dr., suite 500, Atlanta, GA, 30329, USA. privapo@emory.edu.
Abstract
PURPOSE OF REVIEW: The purpose of this paper is to provide a review of the use of ketamine as an antidepressant for treatment-resistant depression (TRD) in the geriatric population. Available treatment options for late-life treatment-resistant depression are limited and include electroconvulsive therapy and transcranial magnetic stimulation as well as possible pharmacologic augmentation. Ketamine has been shown to be a promising treatment in TRD; however, data regarding the use of ketamine in the elderly includes only five case reports. RECENT FINDINGS: We discuss the use of ketamine for late-life TRD and present two cases where ketamine led to a significant and sustained improvement in depressive symptoms. Ketamine is a promising treatment for geriatric patients with TRD. Further studies in the elderly will provide valuable insights into the use of ketamine for a population much in need of safe and effective treatments for TRD.
PURPOSE OF REVIEW: The purpose of this paper is to provide a review of the use of ketamine as an antidepressant for treatment-resistant depression (TRD) in the geriatric population. Available treatment options for late-life treatment-resistant depression are limited and include electroconvulsive therapy and transcranial magnetic stimulation as well as possible pharmacologic augmentation. Ketamine has been shown to be a promising treatment in TRD; however, data regarding the use of ketamine in the elderly includes only five case reports. RECENT FINDINGS: We discuss the use of ketamine for late-life TRD and present two cases where ketamine led to a significant and sustained improvement in depressive symptoms. Ketamine is a promising treatment for geriatric patients with TRD. Further studies in the elderly will provide valuable insights into the use of ketamine for a population much in need of safe and effective treatments for TRD.
Authors: Christian Knöchel; Gilberto Alves; Benedikt Friedrichs; Barbara Schneider; Anna Schmidt-Rechau; Sofia Wenzler; Angelina Schneider; David Prvulovic; André F Carvalho; Viola Oertel-Knöchel Journal: Curr Neuropharmacol Date: 2015 Impact factor: 7.363
Authors: Alessia Mastrodonato; Ina Pavlova; Noelle C Kee; Van Anh Pham; Josephine C McGowan; J John Mann; Christine A Denny Journal: Int J Neuropsychopharmacol Date: 2022-06-21 Impact factor: 5.678
Authors: Alessia Mastrodonato; Ina Pavlova; Noelle Kee; Josephine C McGowan; J John Mann; Christine A Denny Journal: Front Neurosci Date: 2022-04-21 Impact factor: 4.677